Drug Trial Radar · NCT07743931
Study on the Management of COMISA
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Sep 30, 2026
Primary completion
Sep 2028
Study completion Sep 2029
Sponsor
- Lead sponsor
- University Hospital, GrenobleAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Polyclinique Saint-Laurent - Hospitalité Saint-Thomas de Villeneuve; Hôpital Européen Marseille; Centre Médical les Jasmins "Poumon et Sommeil"; Hôpital de la Pitié Salpêtrière - AP-HP
- First posted
- Aug 4, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
COMISA, the combination of obstructive sleep apnea (OSA) and insomnia, is a frequent and burdensome condition. Many patients with OSA experience clinically significant insomnia symptoms, and a substantial proportion of individuals with chronic insomnia also meet criteria for OSA. This comorbidity is associated with more severe symptoms, more complex diagnostic pathways, and reduced adherence to continuous positive airway pressure (CPAP) therapy. This study aims to better understand COMISA and evaluate whether adding daridorexant to CPAP treatment can improve treatment adherence and overall patient outcomes.
Conditions
- Obstructive Sleep Apnea (OSA)
- Insomnia
- COMISA
Interventions
Daridorexant 50 mgDrug
Daridorexant initiated for 1 month before CPAP and prescribed as part of routine care.
Continuous Positive Air Pressure (CPAP)Device
PAP therapy initiated after 1 month of Daridorexant, according to standard clinical practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate, in patients diagnosed with COMISA and treated with CPAP, the impact of daridorexant on CPAP adherence at 4 months compared with patients not receiving daridorexant.Time frame: 4 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
CHU Grenoble Alpes
Grenoble, France · Recruiting
Hôpital Européen Marseille
Marseille, France · Not yet recruiting
Centre Médical Les Jasmins
Metz, France · Not yet recruiting
Hôpital de la Pitié Salpêtrière - AP-HP
Paris, France · Not yet recruiting
Polyclinique Saint-Laurent - Hospitalité Saint-Thomas de Villeneuve
Rennes, France · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.